Hikma Pharmaceuticals Plc Siggi Olafsson to step down as Chief Executive (5177M)
May 24 2022 - 6:11AM
UK Regulatory
TIDMHIK
RNS Number : 5177M
Hikma Pharmaceuticals Plc
24 May 2022
This announcement contains inside information.
London, 24 May 2022 - Hikma Pharmaceuticals PLC (Hikma ) today
announces that Siggi Olafsson has resigned as Chief Executive
Officer (CEO), and from Hikma's Board of Directors, to pursue other
opportunities.
Said Darwazah, Hikma's Executive Chairman and former CEO, will
assume all CEO responsibilities, enabling Hikma to continue
delivering its strategy. Siggi will remain available to the Group
until he departs on 24 June 2022.
Said will continue to work closely with the Executive Committee,
including Hikma's three divisional presidents, benefiting from
their significant experience and strong management teams.
Concurrently, Hikma's Board has initiated an externally facilitated
process to identify a new CEO.
Said Darwazah said:
"On behalf of Hikma's Board and the entire Group, I would like
to thank Siggi for his leadership over the past four years.
Together with the Executive Committee, he has worked tirelessly to
drive strategic momentum across all three businesses, especially
during the challenging days of the pandemic. Hikma is on a strong
footing and well positioned for future growth, and we wish Siggi
well for the future".
Siggi Olafsson said:
"It has been a privilege to work for Hikma, and I am proud of
what the entire team has achieved during my tenure. I would like to
thank the Board for their confidence in me throughout the past four
years. I would also like to thank my colleagues around the world
for their exceptional hard work and commitment. I believe that
Hikma has an exciting future and I look forward to seeing the
business go from strength to strength."
-- ENDS -
The person responsible for the release of this announcement on
behalf of Hikma is Peter Speirs (Company Secretary).
Enquiries :
Hikma (Investors)
Susan Ringdal
EVP, Strategic Planning and Global +44 (0)20 7399 2760/ +44 7776
Affairs 477050
Guy Featherstone +44 (0)20 3892 4389/ +44 7795
Senior Investor Relations Manager 896738
Layan Kalisse +44 (0)20 7399 2788/ +44 7970
Investor Relations Analyst 709912
Teneo (Press)
Charles Armitstead + 44 (0) 7703 330269
Camilla Cunningham + 44 (0) 7464 982426
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and
BBB-/stable Fitch)
Hikma helps put better health within reach every day for
millions of people around the world. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the United States (US), the
Middle East and North Africa (MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,700 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
(c)2022 Hikma Pharmaceuticals PLC. All rights reserved.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABCGDUUDDDGDX
(END) Dow Jones Newswires
May 24, 2022 06:11 ET (10:11 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2024 to Jun 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2023 to Jun 2024